IV Ketamine vs. IN Esketamine for MDD TRD
ConditionTreatment Resistant Depression
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorGustavo Vazquez
About this trial
The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations.
Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,
Eligibility criteria
Qualifiers
Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode
Disqualifiers
Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.
Trial design
Treatments tested in this trial
- Low dose IV Ketamine vs. IN Esketamine
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Gustavo Vazquez
Lead sponsor
Queen's University
Sponsor institution
Centre for Addiction and Mental Health
Collaborator
Envision Mind Care
Collaborator
Sunnybrook Health Sciences Centre
Collaborator
Djavad Mowafaghian Centre for Brain Health
Collaborator
Source ClinicalTrials.gov